Fresenius Medical Care AG & Co. KGaA

Earnings Release • Oct 31, 2012

Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,135 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 256,521 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Growth Strategy

With GOAL 13…

…new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

• Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
• Acquisitions of existing clinics to ensure optimized international presence
• Horizontal expansion in the sector of Renal Drugs as well as
• A boosted activity in home therapies

Key Figures - Summary third quarter 2012

Net revenue	\$ 3,418 million	+ 7%
Operating income (EBIT)	\$ 568 million	+ 6%
Net income	\$ 270 million	- 3%
attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
Earnings per share	\$ 0.88	- 4%
Total assets1	\$ 21,860 million
Operating cash flow2	\$ 1,467 million
Employees1	85,368	+ 8%
1 Patients	256,521	+ 12%
Clinics1	3,135	+ 9%
Treatments2	28.6 million	+ 12%
2 as of September 30, 2012

3 in the first nine months of 2012

Goals for 2012 Net revenue ~ \$14.0 billion¹² Net income ~ \$1.14 billion¹² Leverage ratio (Debt/EBITDA) < 3.0

Revenue third quarter 2012 per region (US\$ 3,418 m)

¹This does not include the investment gain in the amount of \$140 million in the first nine months 2012 nor does it consider \$70 million after tax

²We define the ~sign as +/- 0-2% deviation from the respective numbers

Capital expenditures ~ \$700 million

Acquisitions ~ \$1.8 billion

Management Board Supervisory Board

• Kent Wanzek

• Dr. Ben J. Lipps (Chairman) Dr. Gerd Krick (Chairman)

• Rice Powell (Vice Chairman) Dr. Dieter Schenk (Vice Chairman)
• Michael Brosnan Dr. Walter L. Weisman
• Roberto Fusté Rolf A. Classon
• Dr. Emanuele Gatti William P. Johnston
• Dr. Rainer Runte Prof. Dr. Bernd Fahrholz

Share Profile – Key Data

	FME3
Frankfurt Stock Exchange FME
New York Stock Exchange (NYSE) FMS	FMS/P
Reuters: XETRA / Frankfurt Stock Exchange FMEG.DE / FMEG.F FMEG_p.DE / FMEG_p.F
Bloomberg FME GY	FME3 GY
Security Identification Numbers
WKN 578 580	578 583
ISIN DE 0005785802 DE 0005785836
CUSIP No. (NYSE) 358029106 358029205

Financing Instruments and Maturity Profile

	Amount in	Coupon %	Maturity
	million
Credit Agreement Revolver	~\$ 1,250		October 30, 2017
Credit Agreement Term Loan A	\$ 2,6001		October 30, 2017
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen) 2009 - 2014	€ 451		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

¹ at the beginning before amortisation

Share Price Development last 12 months Financial Calendar

Event	Date
Report on Third Quarter 2012:
Quarterly Financial Report:	November 30, 2012
Report on Full Year 2012:	February 26, 2013
Report on First Quarter 2013:	April 30, 2013
Annual General Meeting 2013:	May 16, 2013
Report on Second Quarter 2013:	July 30, 2013
Report on Third Quarter 2013:	November 5, 2013

Capital Structure Contacts

Fresenius Medical Care AG & Co. KGaA Investor Relations & Corporate Communications Else-Kröner-Straße 1 61352 Bad Homburg
Oliver Maier Senior Vice President, Head of IR & CC	P:+49(0)6172-609-2525 F:+49(0)6172-609-2301
Gerrit Jost Vice President	P:+49(0)6172-609-5216
North America Terry L. Morris Vice President	P:+1-800-948-2538 F: +1-615-345-5605